Our Leadership

A talented team of life science experts, industry executives, and experienced advisors, Fervent Pharmaceuticals’ leadership brings deep passion and distinguished expertise to the company’s mission of improving women’s health. Our management team has a diverse background, extensive experience in the pharmaceutical and healthcare industries, and a proven track record of success.

George-optimized

George E. Royster, Jr.

Chief Executive Officer & Founder

The founder and CEO of Fervent Pharmaceuticals, George Royster is responsible for overseeing and guiding the strategic direction of the company. He is currently preparing the company to conduct a Phase 2 trial, identifying strategic partners (subcontract partners, regulatory consultants, etc.) for outsourcing various aspects of the trial, and ensuring that the trial is adequately financed and successfully concluded.

As CEO, Mr. Royster has recruited the best collaborative strategic partners, including Quintiles and University of Iowa Pharmaceuticals. He has championed a successful Pilot Study of FP-101, demonstrating a 90% efficacy rate, and led the company to a successful Pre-IND meeting with the FDA.

Prior to starting Fervent Pharmaceuticals, Mr. Royster has over 25 years experience in healthcare executive management. He has assisted healthcare organizations in the areas of productivity and profitability by way of operations management, business and service line development. He is credited with over a dozen US and international patents, and is currently hard at work ensuring that Fervent is awarded its remaining international patents pending.

Mr. Royster was the Founder and CEO of a company that provided executive management, expertise, and oversight to healthcare systems, multi-specialty medical practices, and physican offices.

He holds a Bachelor of Business Administration degree from NC Wesleyan College.

Doug Martin

Chief Financial Officer

As CFO of Fervent Pharmaceuticals, Doug Martin oversees the financial and accounting ventures, while providing sound advice to its management team.

Since 2012, Doug has also managed the Wordsworth Family Office thru Brigade Properties LLC, and sits on the board of directors of several companies. Previously, Mr. Martin was the Tax Director and Assistant to the President of MBM Corporation prior to the company being acquired by Berkshire Hathaway.

Mr. Martin has an accounting degree from NC State University and is a CPA.

Advisory Council

Steve Wordsworth
Partner and Advisor
Steve A. Wordsworth is the previous Vice-President and Part Owner of MBM Corporation, a food distributor for national restaurant chains. He is currently a partner in the ownership group of the Carolina Panthers, as well as Redneck Riviera™, Critical Capabilities, Fervent Pharmaceuticals, FintronX, and TrendShift.

Displaying a wide range of interests, Mr. Wordsworth is involved in many other organizations and companies through ownership and investment. Some of these interests include farming, timber management, and real estate.

Mr. Wordsworth is a graduate of North Carolina Wesleyan College. He lives in Rocky Mount, North Carolina, with his wife Elaine and children Josh, Brice, and Rachel.

David LaVance
Partner and Advisor
Mr. LaVance is the former Chairman of the Board of Hologic, Inc., a medical device and diagnostics company headquartered in Boston (HOLX). He is also the Chairman of Integrated Environmental Technologies, Ltd. (IEVM), a public company specializing in providing disinfectants and biocides to industry, as well as President of LifeSource Health, Inc., a medical data access provider.

Mr. LaVance specializes in developing life science and other emerging technology companies as well as in advising companies about mergers, acquisitions, divestitures, and strategic alliances. He has extensive experience in strategic planning for biotechnology and medical device companies, technology licensing, and international distribution.

In 2015, he was one of three finalists for a New York Stock Exchange Leadership award, in the Nonexecutive Chairman of the Year category. NYSE.

Doug Martin
Partner and Advisor
Since 2012, Doug has managed the Wordsworth Family Office thru Brigade Properties LLC, and sits on the board of directors of several companies. Previously, Mr. Martin was the Tax Director and Assistant to the President of MBM Corporation prior to the company being acquired by Berkshire Hathaway.

Mr. Martin has an accounting degree from NC State University and is a CPA.

Lynn Carter, PhD
Advisor
Dr. Lynn Carter provides CMC, pharmaceutical development, and analytical chemistry expertise for a variety of dosage forms in all stages of development. She specializes in CMC project leadership, strategic and technical input on all aspects of CMC development, and authoring of regulatory submissions.

As a consultant, Dr. Carter has worked with a wide range of clients, from large pharma to small virtual companies. She had an eleven-year career at GlaxoSmithKline during which she rose to the position of Manager, PD Operations. Before that she held positions at Procter & Gamble and Pfizer.

Dr. Carter has a Ph.D. Analytical Chemistry, from the University of Cincinnati and a BS in Chemistry from Duke University.

Kristen Buck, MD
Advisor
As Quintiles’ Vice President, Strategic Drug Development Advisory Services, Dr. Kristen Buck provides strategic guidance to sponsors in the planning and design of new drugs and biologics. She is also the co-chair of the company’s Protocol Review Committee.

Dr. Buck has held multiple leadership roles within the pharmaceutical industry, including Medical Officer at the United States Food and Drug Administration (FDA), where she was responsible for sponsor guidance on drug development strategies (Phases I-IV) and review of new drug applications. She also served as Chief Medical Officer for a global medical device company.

She received her Doctor of Medicine degree from Penn State University and a Bachelors in Biochemistry from University of Virginia. She is a certified member of the American Board of Internal Medicine.

Tara Rheault, PhD
Advisor
In her role as Principal Scientific Advisor, Advisory Services, for Quintiles, Dr. Tara Rheault is currently acting as a Project Manager for Fervent. She works with the teams at Fervent and Quintiles to help initiate, plan, and manage the FP-101 product development program

Dr. Rheault has a deep knowledge of cross-functional leadership in drug discovery and development; project, program and portfolio strategy; and management. Her therapeutic area expertise includes respiratory, oncology, dermatology, musculoskeletal, and rare diseases.

Prior to joining Quintiles, Dr. Rheault earned fourteen years of high-impact leadership experience in the pharmaceutical industry at GSK and at Stiefel, a GSK company.

Dr. Rheault has a Doctor of Philosophy in Organic Chemistry from North Dakota State University, where she was an NSF Graduate Fellow.

A talented team of life science experts, industry executives, and experienced advisors, Fervent Pharmaceuticals’ leadership brings deep passion and distinguished expertise to the company’s mission of improving women’s health. Our management team has a diverse background, extensive experience in the pharmaceutical and healthcare industries, and a proven track record of success.

George E. Royster, Jr.

Chief Executive Officer & Founder

The founder and CEO of Fervent Pharmaceuticals, George Royster is responsible for overseeing and guiding the strategic direction of the company. He is currently preparing the company to conduct a Phase 2 trial, identifying strategic partners (subcontract partners, regulatory consultants, etc.) for outsourcing various aspects of the trial, and ensuring that the trial is adequately financed and successfully concluded.

As CEO, Mr. Royster has recruited the best collaborative strategic partners, including Quintiles and University of Iowa Pharmaceuticals. He has championed a successful Pilot Study of FP-101, demonstrating a 90% efficacy rate, and led the company to a successful Pre-IND meeting with the FDA.

Prior to starting Fervent Pharmaceuticals, Mr. Royster has over 25 years experience in healthcare executive management. He has assisted healthcare organizations in the areas of productivity and profitability by way of operations management, business and service line development. He is credited with over a dozen US and international patents, and is currently hard at work ensuring that Fervent is awarded its remaining international patents pending.

Mr. Royster was the Founder and CEO of a company that provided executive management, expertise, and oversight to healthcare systems, multi-specialty medical practices, and physican offices.

He holds a Bachelor of Business Administration degree from NC Wesleyan College.

George-optimized

Doug Martin

Chief Financial Officer

As CFO of Fervent Pharmaceuticals, Doug Martin oversees the financial and accounting ventures, while providing sound advice to its management team.

Since 2012, Doug has also managed the Wordsworth Family Office thru Brigade Properties LLC, and sits on the board of directors of several companies. Previously, Mr. Martin was the Tax Director and Assistant to the President of MBM Corporation prior to the company being acquired by Berkshire Hathaway.

Mr. Martin has an accounting degree from NC State University and is a CPA.

Advisory Council

Steve Wordsworth
Partner and Advisor
Steve A. Wordsworth is the previous Vice-President and Part Owner of MBM Corporation, a food distributor for national restaurant chains. He is currently a partner in the ownership group of the Carolina Panthers, as well as Redneck Riviera™, Critical Capabilities, Fervent Pharmaceuticals, FintronX, and TrendShift.

Displaying a wide range of interests, Mr. Wordsworth is involved in many other organizations and companies through ownership and investment. Some of these interests include farming, timber management, and real estate.

Mr. Wordsworth is a graduate of North Carolina Wesleyan College. He lives in Rocky Mount, North Carolina, with his wife Elaine and children Josh, Brice, and Rachel.

David LaVance
Partner and Advisor
Mr. LaVance is the former Chairman of the Board of Hologic, Inc., a medical device and diagnostics company headquartered in Boston (HOLX). He is also the Chairman of Integrated Environmental Technologies, Ltd. (IEVM), a public company specializing in providing disinfectants and biocides to industry, as well as President of LifeSource Health, Inc., a medical data access provider.

Mr. LaVance specializes in developing life science and other emerging technology companies as well as in advising companies about mergers, acquisitions, divestitures, and strategic alliances. He has extensive experience in strategic planning for biotechnology and medical device companies, technology licensing, and international distribution.

In 2015, he was one of three finalists for a New York Stock Exchange Leadership award, in the Nonexecutive Chairman of the Year category. NYSE.

Doug Martin
Partner and Advisor
Since 2012, Doug has managed the Wordsworth Family Office thru Brigade Properties LLC, and sits on the board of directors of several companies. Previously, Mr. Martin was the Tax Director and Assistant to the President of MBM Corporation prior to the company being acquired by Berkshire Hathaway.

Mr. Martin has an accounting degree from NC State University and is a CPA.

Lynn Carter, PhD
Advisor
Dr. Lynn Carter provides CMC, pharmaceutical development, and analytical chemistry expertise for a variety of dosage forms in all stages of development. She specializes in CMC project leadership, strategic and technical input on all aspects of CMC development, and authoring of regulatory submissions.

As a consultant, Dr. Carter has worked with a wide range of clients, from large pharma to small virtual companies. She had an eleven-year career at GlaxoSmithKline during which she rose to the position of Manager, PD Operations. Before that she held positions at Procter & Gamble and Pfizer.

Dr. Carter has a Ph.D. Analytical Chemistry, from the University of Cincinnati and a BS in Chemistry from Duke University.

Kristen Buck, MD
Advisor
As Quintiles’ Vice President, Strategic Drug Development Advisory Services, Dr. Kristen Buck provides strategic guidance to sponsors in the planning and design of new drugs and biologics. She is also the co-chair of the company’s Protocol Review Committee.

Dr. Buck has held multiple leadership roles within the pharmaceutical industry, including Medical Officer at the United States Food and Drug Administration (FDA), where she was responsible for sponsor guidance on drug development strategies (Phases I-IV) and review of new drug applications. She also served as Chief Medical Officer for a global medical device company.

She received her Doctor of Medicine degree from Penn State University and a Bachelors in Biochemistry from University of Virginia. She is a certified member of the American Board of Internal Medicine.

Tara Rheault, PhD
Advisor
In her role as Principal Scientific Advisor, Advisory Services, for Quintiles, Dr. Tara Rheault is currently acting as a Project Manager for Fervent. She works with the teams at Fervent and Quintiles to help initiate, plan, and manage the FP-101 product development program

Dr. Rheault has a deep knowledge of cross-functional leadership in drug discovery and development; project, program and portfolio strategy; and management. Her therapeutic area expertise includes respiratory, oncology, dermatology, musculoskeletal, and rare diseases.

Prior to joining Quintiles, Dr. Rheault earned fourteen years of high-impact leadership experience in the pharmaceutical industry at GSK and at Stiefel, a GSK company.

Dr. Rheault has a Doctor of Philosophy in Organic Chemistry from North Dakota State University, where she was an NSF Graduate Fellow.

Contact Us

740 Greenville Blvd.Suite 400–151
Greenville, NC 27858